John Tsai
Director/Board Member bei BLUEPRINT MEDICINES CORPORATION
Vermögen: 2 Mio $ am 31.03.2024
Aktive Positionen von John Tsai
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Director/Board Member | 06.01.2023 | - |
| Independent Dir/Board Member | 06.01.2023 | - | |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Private Equity Investor | - | - |
| Forcefield Therapeutics Ltd. | Chief Executive Officer | 27.09.2023 | - |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Chairman | 16.10.2023 | - |
| Corporate Officer/Principal | 16.10.2023 | - |
Karriereverlauf von John Tsai
Ehemalige bekannte Positionen von John Tsai
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| NOVARTIS AG | Chief Tech/Sci/R&D Officer | 01.05.2018 | 15.05.2022 |
| Private Equity Investor | 01.05.2018 | 15.05.2022 | |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 01.01.2017 | 01.01.2018 |
| BRISTOL-MYERS SQUIBB COMPANY | Private Equity Investor | 01.01.2006 | 01.01.2012 |
| Corporate Officer/Principal | 01.01.2012 | 01.01.2017 | |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Director/Board Member | - | - |
Ausbildung von John Tsai
| Washington University in St. Louis | Undergraduate Degree |
| University of Louisville School of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 8 |
| Vereinigtes Königreich | 3 |
| Schweiz | 2 |
Operativ
| Private Equity Investor | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
Sektoral
| Health Technology | 6 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| NOVARTIS AG | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Health Technology |
| Forcefield Therapeutics Ltd. |
